/
Neurology
Narcolepsy
8
Pipeline Programs↗
7
Active Trials↗
13
Companies Involved↗
Narcolepsy is an early-stage landscape with 8 programs across 13 companies. The most active players are NLS Pharmaceutics, Eisai, Jazz Pharmaceuticals. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 21
Phase 31
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
6 of 7 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 88% of 8 pipeline programs.
Analysis
Trial Status
55
clinical trials
Completed42 · 76%
Recruiting5 · 9%
Terminated4 · 7%
Not yet recruiting2 · 4%
No longer available2 · 4%
Clinical Trials
Trial Activity
55 trials
Risk of Narcolepsy Associated With Administration of H1N1 Vaccine
Completed·CCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal·N/A·NCT01394614·24 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)